Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes

European Journal of Pharmacology

Volumn 367, Issue 2-3, 1999, Pages 343-350

  Denis, Danielle ^a   Riendeau, Denis ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

fMLP (N formyl Met Leu Phe); Leukotriene biosynthesis; Phosphodiesterase; Phosphodiesterase inhibitor; Polymorphonuclear leukocyte

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; CALCIMYCIN; CHEMOTACTIC PEPTIDE; CYCLIC AMP; FORMYLMETHIONYLLEUCYLPHENYLALANINE; ISOBUTYLMETHYLXANTHINE; KF 18280; LEUKOTRIENE B4; MILRINONE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; QUAZINONE; RS 14203; RS 25344; UNCLASSIFIED DRUG; ZAPRINAST;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL;

CYCLIC AMP; DINOPROSTONE; HUMANS; ISOPROTERENOL; LEUKOTRIENE B4; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SURGICAL FLAPS; SYMPATHOMIMETICS; TIME FACTORS;

EID: 0033043885     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00987-X     Document Type: Article

References (34)

1. Alvarez R., Sette C., Yang D., Eglen R.M., Wilhelm R., Shelton E.R., Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48:1995;612-622.
2. 4) with anti-inflammatory properties. In: Schudt, C., Dent, G., Rabe, K. (Eds.), The Handbook of Immunopharmacology, Phosphodiesterase Inhibitors. Clive Page, London, pp. 161-171.
3. Alves A.C., Pires A.L.A., Cruz H.N., Serra M.F., Diaz B.L., Cordeiro R.S.B., Lagente V., Martins M.A., Esilva P.M.R. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur. J. Pharmacol. 312:1996;89-96.
4. Anderson R., Goolam Mahomed A., Theron A.J., Ramafi G., Feldman C. Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in fMLP-activated human neutrophils. Br. J. Pharmacol. 124:1998;547-555.
5. Banner K.H., Moriggi E., Da Ros B., Schioppacassi G., Semero C., Page C.P. The effects of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br. J. Pharmacol. 119:1996;1255-1261.
6. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75(4):1995;725-747.
7. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
8. Bushnik T., Conti M. Role of multiple cAMP-specific phosphodiesterase variants. Biochem. Soc. Trans. 24:1996;1014-1019.
9. 4. J. Biol. Chem. 272:1997;9854-9859.
10. Dent G., Giembycz M.A., Evans P.M., Rabe K.F., Barnes P.J. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther. 271:1994;1167-1174.
11. Gillard J., Ford-Hutchinson A.W., Chan C., Charleson S., Denis D., Foster A., Fortin R., Leger S., Mcfarlane C.S., Morton H., Piechuta H., Riendeau D., Rouzer C.A., Rokach J., Young R., MacIntyre D.E., Peterson L., Bach T., Eiermann G., Hopple S., Hupe L., Luell S., Metzger J., Meurer R., Opas E., Pacholok S. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethyl- propanoic acid) a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67:1989;456-464.
12. Hamel P., Riendeau D., Brideau C., Chan C.-C., Desmarais S., Delorme D., Dube D., Ducharme Y., Ethier D., Grimm E., Falgueyret J.-P., Guay J., Jones T.R., Kwong E., Mcauliffe M., Mcfarlane C.S., Piechuta H., Roumi M., Tagari P., Young R.N., Girard Y. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors: synthesis, biological profile and pharmacokinetics of L-739,010. J. Med. Chem. 40:1997;2866-2875.
13. 4A cAMP-specific phosphodiesterase determine intracellular targeting and regulation of catalytic activity. Biochem. Soc. Trans. 24:1996;980-986.
14. Hughes B., Howat D., Lisle H., Holbrook M., James T., Gozzard N., Blease K., Hughes P., Kingaby R., Warrelow G., Alexander R., Head J., Boyd E., Eaton M., Perry M., Wales M., Smith B., Owens R., Catterall C., Lumb S., Russell A., Allen R., Merriman D., Bloxham D., Higgs G. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118:1996;1183-1191.
15. 4 inhibitors: the use of molecular cloning in the design and development of novel drugs. DDT. 2:1997;89-101.
16. Klotz K.-N., Jesaitis A. Neutrophil chemoattractant receptors and the membrane skeleton. BioEssays. 16:1994;193-198.
17. Krump E., Borgeat P. Kinetics of 5-lipoxygenase activation, arachidonic acid release and leukotriene synthesis in human neutrophils: effects of granulocyte-macrophage colony-stimulating factor. Biochim. Biophys. Acta. 1213:1994;135-139.
18. Krump E., Pouliot M., Naccache P.H., Borgeat P. Leukotriene synthesis in calcium-depleted human neutrophils: arachidonic acid release correlates with calcium influx. Biochem. J. 310:1995;681-688.
19. Lombardo L.J. Phosphodiesterase-IV inhibitors: novel therapeutics for the treatment of inflammatory diseases. Current Pharmaceutical Design. 1:1995;255-268.
20. Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101:1995;387-389.
21. Moraes V.L.G., Singer M., Vargaftig B.B., Chignard M. Effects of rolipram and cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung. Br. J. Pharmacol. 123:1998;631-636.
22. Müller T., Engels P., Fozard J. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharm. Sci. 17:1996;294-298.
23. Nielson C.P., Crowley J.J., Morgan M.E., Vestal R.E. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3′,5′-adenosine monophosphate. Am. Rev. Respir. Dis. 137:1988;25-30.
24. Nielson C.P., Vestal R.E., Sturm R.J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86:1990;801-808.
25. Peachell P.T., Undem B.J., Schleimer R.P., Macglashan D.W. Jr., Lichtenstein L.M., Cieslinski L.B., Torphy T.J. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148:1992;2503-2510.
26. i. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;682-690.
27. 4 cyclic AMP phosphodiesterases. Cell. Signal. 9:1997;227-236.
28. Souness J.E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M.N., Ashton M.J., Karlsson J.-A. Suppression of eosinophil function by RP-73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol. 115:1995;39-46.
29. Suzuki F., Kuroda T., Tamura T., Sato S., Ohmori K., Ichikawa S. New anti-inflammatory agents: 2. 5-Phenyl-3H-imidazo[1,8]naphthyridin-4(5H)-ones: a new class of non-steroidal anti-inflammatory agents with potent activity like glucocorticoids. J. Med. Chem. 35:1992;2863-2870.
30. Tenor, H., Schudt, C., 1996. 2. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In: Schudt, C., Dent, G., Rabe, K. (Eds.), The Handbook of Immunopharmacology, Phosphodiesterase Inhibitors, Clive Page, London, pp. 21-40.
31. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 118:1996;1727-1735.
32. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
33. Torphy T.J., Barnette M., Hay D.W.P., Underwood D.C. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ. Health Perspect. 102:1994;79-84.
34. Villagrasa V., Navarrete C., Sanz C., Berto L., Perpiña M., Cortijo J., Morcillo E.J. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes. Methods Find. Exp. Clin. Pharmacol. 18:1996;239-245.